📈 Jumpstart Signal Watchlist — August 13, 2026

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $12.67 is 14% below 3yr high $14.66 · ⏳ SMA200 $9.26 (current price $12.67 is above) · 💰 Market Cap $1.2B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 36/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; SMA50 recent crossover; EPS growth 456% (>20%); PEG ratio 0.04 (<1.5).
⏰ Entry (E): 0/20
- 📈 RSI at 54 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ MeiraGTx Reports Second Quarter 2026 Financial and Operational Results — GlobeNewswire.
🤖 MeiraGTx reported second-quarter 2026 results with diluted net income per ordinary share of $1.71, and the release highlighted increased cash and meaningful service revenue from its Lilly collaboration. The strong earnings beat and corporate update are favorable for the stock.
✅ Why is MeiraGTx stock surging today? — Investing.com.
🤖 This article says the stock jumped after MeiraGTx’s second-quarter 2026 results came in far ahead of expectations, with EPS of $1.71 versus a loss estimate and revenue of $321.4 million versus a much lower consensus. It also notes several strategic catalysts, including FDA Breakthrough Therapy Designation and a $400 million Oberland Capital agreement, which are positive for sentiment.
✅ MeiraGTx (NASDAQ:MGTX) Releases Quarterly Earnings Results, Beats Expectations By $2.17 EPS — MarketBeat.
🤖 The article reports that MeiraGTx beat quarterly EPS expectations by $2.17, with earnings of $1.71 versus the consensus loss estimate. A large earnings beat is typically supportive for the share price.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: BioCryst Pharmaceuticals is a biotechnology company that develops and commercializes medicines for hereditary angioedema (HAE) and other rare diseases. Its key products include ORLADEYO for preventing HAE attacks and RAPIVAB for treating influenza, and it is also advancing additional rare-disease drug candidates.
- 🎯 Current $9.81 is 12% below 3yr high $11.19 · ⏳ SMA200 $8.33 (current price $9.81 is above) · 💰 Market Cap $2.5B
- BCRX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 26/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1400% (>20%); Revenue growth 34% (>15%).
⏰ Entry (E): 8/20
- 🔔 SMA20/SMA50 bullish crossover
- 📈 RSI at 53 in healthy mid-range
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ BioCryst Pharmaceuticals Q2 Earnings Call Highlights — Finance Yahoo.
🤖 BioCryst reported strong Q2 operating momentum, including rising ORLADEYO revenue, the start of pediatric shipments, and completion of enrollment in the navenibart trial. The company also maintained its 2026 ORLADEYO outlook and advanced its pipeline, which is constructive for the stock.
✅ BioCryst Pharmaceuticals (BCRX) Tops Q2 Earnings and Revenue Estimates — Finance Yahoo.
🤖 BioCryst beat Q2 earnings expectations and also exceeded revenue estimates. Earnings and revenue beats typically support the stock because they signal stronger-than-expected operating performance.
⚪️ BioCryst Pharmaceuticals (BCRX) Stock Price Down 5.7% - Here's What Happened — MarketBeat.
🤖 This article is mixed: it highlights a sharp one-day share decline, but it also notes BioCryst’s Q2 earnings beat, raised revenue guidance, and broadly positive analyst ratings. The stock move itself is negative, but the operational and guidance details are supportive for BCRX.
⚪️ RBC Adjusts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Outperform Rating — Finance Yahoo.
🤖 RBC lowered its price target but kept an Outperform rating, which is a mixed signal. The reduced target is a modest negative, but the maintained positive rating keeps the overall impact closer to neutral.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Remitly Global, Inc. is a digital financial services provider that offers cross-border remittance and international money transfer services primarily for immigrants and their families through a mobile app and website .
- 🎯 Current $25.62 is 7% below 3yr high $27.59 · ⏳ SMA200 $17.76 (current price $25.62 is above) · 💰 Market Cap $5.4B
- RELY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 53/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 3000% (>20%); Revenue growth 20% (>15%); ROE 27% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (7.3%)
- 🔔 Strong above EMA50 (12.0%)
- 📈 RSI at 60 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Remitly Global earnings beat by $0.80, revenue topped estimates — Investing.com.
🤖 Remitly reported second-quarter EPS of $0.93 and revenue of $495.2 million, both above analyst estimates. The article also says the company raised full-year revenue guidance and Q3 revenue guidance came in slightly above consensus, which is supportive for the stock.
✅ Remitly Reports Record Second Quarter Results and Raises Full-Year 2026 Outlook — GlobeNewswire.
🤖 Remitly said Q2 revenue rose 20% year over year to $495.2 million and adjusted EBITDA increased 79% to $114.7 million. It also raised its full-year 2026 outlook, which is typically positive for valuation and investor sentiment.
✅ Why Remitly Global Stock Popped 8% Today — Yahoo Finance.
🤖 The article says the stock moved higher after Remitly posted better-than-expected second-quarter earnings. That kind of post-earnings price reaction reflects a positive market response to the results.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $51.82 is 7% below 3yr high $55.72 · ⏳ SMA200 $38.78 (current price $51.82 is above) · 💰 Market Cap $2.7B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ John Wiley & Sons A stock hits 52-week high at 53.28 USD — Investing.com.
🤖 Wiley shares reached a new 52-week high, which is generally bullish for the stock price. The article also notes that the company recently reported fiscal Q4 2026 earnings above analyst EPS expectations, reinforcing the positive tone.
✅ John Wiley & Sons (NYSE:WLY) Sets New 52-Week High — MarketBeat.
🤖 The stock hit a new 52-week high during trading, signaling strong recent momentum. This kind of price-strength article is typically positive for investor sentiment, even though it does not add new fundamental information.
✅ HPE, WLY Also Gain On Joining Federal AI Initiative — Yahoo Finance.
🤖 Shares of Wiley rose after the company announced a role in the Department of Energy's Genesis Mission. Participation in a major federal AI initiative can be viewed as a positive strategic development for the stock.
🍭 Bonus (B): 0/10 — Book Publishing

🏢 What they do: TechnipFMC plc (NYSE: FTI) is a technology provider to the traditional and new energy industries, delivering fully integrated projects, products, and services through its two main segments: Subsea and Surface Technologies.
- 🎯 Current $76.67 is 0% below 3yr high $76.99 · ⏳ SMA200 $61.12 (current price $76.67 is above) · 💰 Market Cap $30.1B
- FTI shows decent technicals supported by positive sentiment.

💎 Quality (Q): 51/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 41% (>20%); ROE 36% (>15%); Low LT D/E 0.12 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (5.9%)
- 📈 RSI at 63 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ TechnipFMC Q2 Earnings & Revenues Beat Estimates — Yahoo Finance.
🤖 TechnipFMC reported Q2 2026 adjusted EPS of 91 cents, above estimates, and also beat revenue expectations. The report also highlighted a quarterly dividend and a large share buyback, both supportive for shareholder returns.
✅ TechnipFMC PLC (FTI) (Q2 2026) Earnings Call Highlights — Yahoo Finance.
🤖 This summary of the Q2 call points to strong revenue, higher adjusted EBITDA, strong free cash flow, and increased full-year adjusted EBITDA guidance. It also notes $2.5 billion of subsea orders, which is a constructive sign for future growth.
✅ TechnipFMC beats Q2 2026 estimates, raises outlook — Investing.com.
🤖 The article says TechnipFMC beat second-quarter earnings and revenue expectations and lifted its full-year profit outlook. Although the stock dipped in premarket trading, the underlying business update was favorable for the stock.
🍭 Bonus (B): 0/10 — Oil & Gas Field Machinery

🏢 What they do: Avnet, Inc. is a global distributor of electronic components and a technology solutions provider that supports engineers, entrepreneurs, and startups in taking tech projects from idea and design to prototype and mass production.
- 🎯 Current $95.99 is 1% below 3yr high $97.40 · ⏳ SMA200 $67.79 (current price $95.99 is above) · 💰 Market Cap $7.9B
- AVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1578% (>20%); Revenue growth 48% (>15%); Low LT D/E 0.39 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 62 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Avnet Reports Fourth Quarter and Fiscal 2026 Financial Results — Yahoo Finance.
🤖 Avnet reported record fourth-quarter sales of $8.3 billion and adjusted diluted EPS of $2.28, both well above the prior year and above expectations. The company also issued first-quarter guidance calling for continued growth in sales and EPS, which is constructive for the stock.
✅ Avnet Q4 FY26 slides: record $8.3B revenue, 48% growth across regions — Investing.com.
🤖 This article highlights that Avnet’s fiscal fourth-quarter results beat Wall Street estimates by a wide margin, with record revenue and strong EPS growth. The broad-based regional recovery and margin expansion are positive signals for investor sentiment.
✅ Avnet (AVT) Q4 2026 Earnings Call Transcript — The Motley Fool.
🤖 The transcript emphasizes record sales, strong adjusted EPS growth, and margin expansion across Avnet’s businesses. Management’s guidance for higher sales and EPS in the next quarter adds to the favorable outlook.
🍭 Bonus (B): 0/10 — Electronic Parts - Wholesale

🏢 What they do: Ziff Davis is a digital media and internet company that operates a portfolio of online brands and services across technology, shopping, gaming, entertainment, health and wellness, connectivity, cybersecurity, and marketing technology.
- 🎯 Current $55.91 is 22% below 3yr high $71.80 · ⏳ SMA200 $41.06 (current price $55.91 is above) · 💰 Market Cap $2.0B
- ZD shows decent technicals supported by positive sentiment.

💎 Quality (Q): 50/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 2668% (>20%); ROE 29% (>15%); Low LT D/E 0.39 (<1.0); Near-high ROE setup (52wk high + ROE).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (5.0%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 61 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Ziff Davis Q2 2026 Earnings Call Highlights — MarketBeat.
🤖 Ziff Davis reported a beat on adjusted EPS, completed its $1.2 billion Connectivity sale, and said free cash flow doubled year over year. Although revenue and EBITDA declined, the balance-sheet improvement and stronger per-share results are supportive for the stock.
✅ Ziff Davis Reports Second Quarter 2026 Financial Results — Yahoo Finance / Business Wire.
🤖 The company reported second-quarter results with adjusted EPS above expectations and highlighted the completed sale of its Connectivity business. The results also showed substantial share repurchases and a large cash position, which likely support valuation despite lower revenue.
✅ Ziff Davis Q2 2026 slides: EPS rises 13% as buybacks offset revenue slip — Investing.com.
🤖 This report emphasizes that adjusted EPS rose 13.2% even as consolidated revenue declined, largely because of aggressive buybacks and operational discipline. The article also notes the company’s revenue decline was smaller than in prior quarters, suggesting improving trends.
🍭 Bonus (B): 0/10 — Telegraph & Other Communications